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Abstract
Background: A loss of function of the L-type calcium channel, Cav1.2, results in a cardiac specific disease known
as Brugada syndrome. Although many Brugada syndrome channelopathies reduce channel function, one point
mutation in the N-terminus of Cav1.2 (A39V) has been shown to elicit disease a phenotype because of a loss of
surface trafficking of the channel. This lack of cell membrane expression could not be rescued by the trafficking
chaperone Cavb.
Findings: We report that despite the striking loss of trafficking described previously in the cardiac Cav1.2 channel,
the A39V mutation while in the background of the brain isoform traffics and functions normally. We detected no
differences in biophysical properties between wild type Cav1.2 and A39V-Cav1.2 in the presence of either a cardiac
(Cavb2b), or a neuronal beta subunit (Cavb1b). In addition, the A39V-Cav1.2 mutant showed a normal Cavb2b
mediated increase in surface expression in tsA-201 cells.
Conclusions: The Brugada syndrome mutation A39V when introduced into rat brain Cav1.2 does not trigger the
loss-of-trafficking phenotype seen in a previous study on the human heart isoform of the channel.
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Background
Cav1.2 is an L-type voltage-gated calcium channel that
is indispensible for proper function of organs including
the brain and the heart [1]. Structurally, Cav1.2 channel
complexes are composed of a pore-forming Cava1s u b -
unit, an accessory Cava2δ subunit, and a Cavb traffick-
ing chaperone [2] which interacts with the Cava1
subunit at the intracellular region linking the first two
transmembrane domains [3-5]. Extensive alternate spli-
cing of Cav1.2 between neuronal and cardiac back-
grounds alters channel structure and function, as does
the type of Cavb subunit that is expressed in a given tis-
sue [6-9]. Gain of function mutations in Cav1.2 channels
may result in a multi-organ disease known as Timothy
syndrome which is characterized by cardiac symptoms
such as a prolonged Q-T interval, arrhythmias and
sudden cardiac death (SCD); as well as immune dys-
function and autism [10]. A loss of Cav1.2 function on
the other hand, can give rise to a heart specific disorder
termed Brugada syndrome whose phenotype consists of
a shortened Q-T interval, ventricular fibrillation and
SCD [10]. Brugada syndrome has been associated with a
gain of function in KCNE potassium channels [11], as
well as a loss of function of Nav1.5 (15% of all cases)
and Cav1.2/Cavb (5% of all cases) [1,12]. How exactly
increased Cav1.2 activity yields a disease phenotype in
heart and brain, whereas reduced function selectively
affects the heart is unknown, but may be explained by
tissue-specific splice isoforms of the channel. Recent
reports of splice isoform specific effects of mutations in
P/Q-type and T-type calcium channels [13,14] may sug-
gest that the tissue selective effect of Brugada syndrome
mutations could be related to Cav1.2 channel sequences
that are specific to the heart.
Recently a point mutation in the N-terminus of
Cav1.2 (A39V) was identified in a patient with Brugada
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function by way of disabled surface trafficking of the L-
type channel complex [1]. The defective surface expres-
sion of A39V-Cav1.2 persisted upon coexpression of the
cardiac Cavb2b subunit, indicating that the effects of the
mutation dominated over the well documented protec-
tive effect of Cavb. This may be due to the possibility
that intracellular linkers other than the I-II linker modu-
late surface expression of Cav1.2. Alternate splicing in
the amino terminus of the channel can alter cell surface
trafficking [6,15,16]. In addition an N-terminal splice
variant specific to the heart termed the ‘long variant’,
imparts PKC regulation upon the channel, while another
shorter variant found in both heart and brain does not
[17,18]. What is more important is that this second N-
terminal variant is common to both the brain isoform
used in our study and the cardiac channel used to test
A39V-Cav1.2 previously. Other key sequence differences
between cardiac and neuronal Cav1.2 variants do exist
however, as do differences between human and rat
channels, which are approximately 95% homologous
(see Additional file 1: Figure S1).
The fact remains that the patient carrying A39V-
Cav1.2 did not present with neurological symptoms rais-
ing the possibility that this mutation does not affect the
sub-cellular trafficking of neuronal Cav1.2 channels.
To test this hypothesis we introduced the A39V muta-
tion into rat brain Cav1.2 channels and examined its
functional consequences in tsA-201 cells. Unlike in pre-
vious work with cardiac Cav1.2, we show that neuronal
A39V-Cav1.2 retains Cavb2b-dependent increases in
surface expression, as well as total expression. We did
not detect any biophysical differences between A39V-
Cav1.2 and WT-Cav1.2 in the presence of either a car-
diac or neuronal Cavb subunit. We thus conclude that
splice isoform differences between cardiac and neuronal
Cav1.2 channels underlie the absence of a brain pheno-
type for the A39V Brugada mutation.
Methods
cDNAs/Mutagenesis
Wild type (WT) rat calcium channel subunit cDNAs
encoding Cav1.2 (a1C), Cavb1b and Cava2δ1 subunits,
as well as the pMT2 vector were generously donated by
Dr. Terry Snutch (University of British Columbia, Van-
couver, BC). Rat Cav1.2 has a polymorphism (glycine at
amino acid position 57) adjacent to the A39V Brugada
mutation locus which is not present in the human car-
diac isoform. To facilitate comparison with previous
work [1], we mutated rat Cav1.2 at position 57 to aspar-
tic acid using QuickChange Site-Directed Mutagenesis
Kit (Stratagene) as per manufacturer’s instructions. The
primer used for the G57D Cav1.2 mutagenesis was
GGCAGGCAGCCATCGACGCCGCCCGGCAGGCC
and its molecular complement. The A39V mutation was
then constructed in both non-tagged and HA tagged
Cav1.2 constructs using the primer AATGCAGCTG-
CAGGACTTGTCCCCGAGCACATCCCTACTCC. Fol-
lowing mutagenesis and cDNA preparation all clones
were sequenced to verify the presence of desired muta-
tions and overall sequence fidelity. The HA tagged ver-
sion of Cav1.2 used has been previously described [19].
The Cavb2b construct was generously donated by Dr.
Henry Colecraft (Columbia University, New York, USA).
GenBank™ accession numbers for the clones used are
as follows: Cav1.2 [M67515], Cavb1b [NM017346],
Cavb2b [AF423193.1], and Cava2δ1 [AF286488].
Tissue culture and transient transfection
Human embryonic kidney tsA-201 cells were grown and
transiently transfected using the calcium phosphate
method as described previously [3]. Transfection solu-
tions for individual culture dishes contained a mixture
of cDNA expression vectors, with the following quanti-
ties of cDNA expression constructs used: WT, or A39V
calcium channel Cav1.2 subunit (3 μg), Cavb subunit (3
μg), Cava2δ1( 3μg) and in addition for electrophysiol-
ogy transfections, 0.25 μg pEGFP marker vector (Clon-
tech). Non-tagged Cav1.2 clones were used for
electrophysiology, while HA-tagged clones were trans-
fected for all other experiments. Transfections which
lacked a Cavb subunit included 3 μgo fp M T 2v e c t o r .
Twelve hours post-transfection cells were washed once
with PBS (pH 7.4), supplemented with fresh DMEM,
and allowed to recover for 12 h. To prevent overgrowth
for electrophysiology, cells were transferred to a 29°C
incubator and maintained for 48-72 h prior to voltage-
clamp recording. For immunoprecipitation/Western blot
and immunofluorescence experiments cells were kept at
37°C for 48-72 h after PBS/DMEM treatment and
grown to 75-85% confluence.
Immunoprecipitation and Western blotting
Cultured tsA-201 cells were transiently transfected as
described above with HA tagged channels for immuno-
precipitation assays and were lysed with a modified
RIPA buffer (in mM; 50 Tris, 130 NaCl, 0.2% triton X-
100, 0.2% NP-40, 5 EGTA, pH 7.4). Lysis was carried
out on ice for 15 min after which cells were centrifuged
at 13, 000 rpm for 5 min at 4°C. Supernatants were then
transferred to new tubes and solubilized proteins were
incubated with 50 μl of Protein G beads (Pierce/Pro-
mega) and 1 μg of HA antibody (Roche) overnight while
tumbling at 4°C. Total inputs were taken from whole
cell samples representing 2.5% of the total protein and
probed for alpha-actin (Sigma). Immunoprecipitates
were washed once with the previously described modi-
fied RIPA buffer and a second time with a high salt
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100, 0.1% NP-40, pH 7.4) and a final time with PBS (pH
7.4). Following washing, beads were aspirated to dryness
and Laemmli buffer was added to samples before incu-
bating at 96°C for 10 min. Eluted samples were loaded
on the appropriate percentage Tris-glycine gel and
resolved using SDS-PAGE. Samples were transferred to
0.45 μm PDVF membranes (Millipore) and western blot
analysis performed using 1/1000 anti-HA (Covance), or
1/1000 anti-actin (Sigma). GE Healthcare horseradish
peroxidase-linked secondary antibodies of appropriate
species (mouse and rabbit) were used at 1/10000 dilu-
tion. Image J (National Institute of Health) was used to
quantify the integrated density of protein on Western
blots. For each blot the background signal was sub-
tracted from experimental integrated densities to obtain
sample values. Background subtracted values for HA
signal were then divided by background subtracted actin
signal to obtain the HA/actin ratio.
Epifluorescence imaging
Cultured tsA-201 cells were transiently transfected as
described above with HA tagged channels. Seventy two
hours after transfection cells were fixed with 4% parafor-
maldehyde, and immunostained with anti-HA (1/1000,
Roche). Alexa Fluor 594-conjugated goat a-rat IgG anti-
body (Molecular Probes, 1/1000) was used as the sec-
ondary antibody. Cells were imaged using a Zeiss LSM-
510 Meta confocal microscope with a 40 × 1.2NA water
immersion lens in the inverted position. The AF-594
antibody was visualized by excitation with a HeNe laser
(543 nm) and emission detected using a 585-615-nm
band pass filter. Image acquisition was performed with
identical gain, contrast, laser excitation, pinhole aperture
(fully open), scan size and laser scanning speed for all
samples. Quantification of fluorescent signal was done
following offline threshold adjustment with Image J. To
obtain values for fluorescence/cell the total fluorescence
per image was divided by the number of cells above
threshold in that image.
Cav1.2 voltage clamp recordings
Glass cover slips carrying cells expressing A39V or WT
Cav1.2 channels (no HA tag) were transferred to a 3.5-
cm culture dish (Corning) containing external recording
solution consisting of 20 mM BaCl2, 1 mM MgCl2,10
mM HEPES, 10 mM Glucose and 136 mM CsCl (pH
7.4 adjusted with CsOH). Micro-electrode patch pipettes
were pulled and polished using a DMZ- Universal Puller
(Dagan Corporation) to a typical resistance of 3-5 MÙ.
Internal pipette solution consisted of 110 mM
CsCH3SO3, 20 mM TEA-Cl, 10 mM EGTA, 2 mM
MgCl2 and 10 mM HEPES (pH 7.2 adjusted with
CsOH).
Whole cell patch clamp recordings were performed in
voltage-clamp mode using an Axopatch 200B amplifier
(Axon Instruments) linked to a personal computer with
pCLAMP software version 9.2. Series resistance was
compensated by 85%, leak currents were negligible, and
the data were filtered at 5 kHz. Individual pEGFP
expressing cells were held at -100 mV. For steady state
inactivation curves, we applied 4.5 s conditioning depo-
larizations, followed by a test pulse to +10 mV for 0.5 s.
Individual sweeps were separated by 15 s. All stable
cells with detectable inward current at 0 mV were used
to calculate current density. Only those cells whose
whole cell current voltage relationships could be fit with
the modified Boltzmann equation, I = (1/(1 + exp
(-(Va-V)/
S)))*(V-Erev)*Gmax,w h e r e‘I’ is current, ‘Va’ is half-activa-
tion potential, ‘V’ is membrane potential, ‘Erev’ is rever-
sal potential, S is the slope factor, and ‘Gmax’ is slope
conductance, were used for determination of voltage-
dependent properties. As well, only cells whose steady-
state inactivation could be fit by the Boltzmann equa-
tion, I/Imax =A 2 +A 1/(1 + exp
((V-Vh)/S)), where ‘I/Imax’ is
normalized current, ‘A2’ is the non-inactivating fraction,
‘A1’ is inactivating fraction, ‘V’ is membrane potential, S
is the slope factor, and ‘Vh’ is half inactivation potential,
were used to calculate voltage-dependent properties of
steady-state inactivation.
Data analysis
All electrophysiological data were analyzed using
Clampfit version 9.2 (Axon Instruments) and fit in Ori-
gin 7 (Origin Lab Corporation). Image J was used to
quantify the integrated density units (IDUs) of protein
on Western blots as describe above. For quantification
of fluorescent images Image J was used as described
above yielding units of Arbitrary Light Units (ALUs).
Statistical analyses for both biochemical and electrophy-
siological data were carried out using Origin 7. All sam-
ple means are reported +/- SEM. Statistically significant
differences between means were assessed using student’s
t-test, or one-way ANOVA at 95% confidence level as
appropriate.
Findings & conclusions
Brugada syndrome mutations contribute to cardiac dis-
ease by shortening the Q-T segment of contraction,
leading to arrhythmia and sudden cardiac death [10].
Functional changes that reduce Cav1.2 conductance can
lead to Brugada syndrome, but so can mutations that
reduce the number of channels in the cell membrane
due to compromised cell surface trafficking. It was
s h o w nt h a tap o i n tm u t a t i o n( A 3 9 V )i nt h eN - t e r m i n u s
of a cardiac isoform of Cav1.2 severely limited mem-
brane expression of the channel even upon coexpression
of the ancillary Cavb2 bs u b u n i t[ 1 ] .T h i si su n e x p e c t e d
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and surface trafficking of the channel by binding the
intracellular linker connecting domains I and II of the
calcium channel a1 subunit [16,20]. Given that Brugada
syndrome does not involve compromised brain function,
we wondered if the A39V mutation might trigger a simi-
lar loss-of-trafficking phenotype in neuronal Cav1.2
channels.
We first examined whether cell surface expression of
A39V-Cav1.2 was different from that of wild type
Cav1.2 (hereafter referred to as WT-Cav1.2) by staining
for an external HA epitope on the channel in non-per-
meablized tsA-201 cells. We found that in the rat brain
channel, surface expression of A39V-Cav1.2-HA (Figure
1A) was visible and that Cavb2b significantly increased
surface expression. Quantification of A39V-Cav1.2-HA
fluorescence determined that the signal per cell (i.e., the
surface pool of channels per cell), was significantly
increased upon co-expression of a Cavb subunit (Figure
1B). We found that WT-Cav1.2-HA and A39V-Cav1.2-
HA were not differentially exp r e s s e da tt h ec e l ls u r f a c e
(7064+/-1211 and 6298 +/-785 ALUs respectively).
Coexpression of Cavb2b significantly increased the sur-
face pools of both WT-Cav1.2-HA (13087 +/- 964
ALUs, p = < 0.05 ANOVA) and A39V-Cav1.2-HA
(12715 +/-1291 ALUs p = < 0.05 ANOVA). Cavb1b was
able to significantly increase the surface pool of WT-
Cav1.2-HA (10145 +/-790 ALUs, p = < 0.05 ANOVA),
and there was a strong trend towards increased surface
expression of A39V-Cav1.2 (10109 +/-842 ALUs), how-
ever, this effect did not reach statistical significance
(also see Additional file 2: Figure S2). Altogether, Figure
1A and 1B show that A39V-Cav1.2 is able to traffic to
the cell membrane as well as WT-Cav1.2, and that the
cardiac Cavb2b subunit significantly increases surface
expression of A39V-Cav1.2 in a neuronal background.
Since previous work showed that Cavb2b was unable to
traffic the cardiac isoform of A39V-Cav1.2 to the cell
membrane [1], the robust Cavb-dependent trafficking
observed in our experiments implies isoform specific
effects for the A39V mutation. Splice variants of the
Cav1.2 N-terminus have been shown to regulate cell
Figure 1 Surface trafficking and total expression are the same for A39V-Cav1.2-HA and WT-Cav1.2-HA in the presence of b2b.( A). b2b
significantly increases the surface trafficking of A39V-Cav1.2-HA and WT-Cav1.2-HA in nonpermeablized tsA-201 cells. (B). Quantification of HA
surface pool displayed as fluorescence per cell (arbitrary light units). b2b and b1b (Additional file 2: Figure S2A) significantly increase the
fluorescence per cell of WT-Cav1.2-HA, while only b2b significantly increased the surface fluorescence of A39V-Cav1.2-HA (*p = < 0.05 and #p =
< 0.05 by one-way ANOVA). Cavb1b does not significantly increase the fluorescence per cell of A39V-Cav1.2 (p = > 0.05 by one-way ANOVA). (C).
Total protein expression of A39V-Cav1.2-HA and WT-Cav1.2-HA from tsA-201 cell lysates expressed with and without b2b. (D). Quantification of
A39V-Cav1.2-HA and WT-Cav1.2-HA total expression (integrated density units) with and without b2b/b1b (Additional file 2: Figure S2B). The data
is expressed as a ratio of HA/a-actin. Both b2b and b1b significantly increase the expression of A39V-Cav1.2 (*p = < 0.05 by one-way ANOVA).
A39V-Cav1.2 shows less expression than WT-Cav1.2 in the absence of Cavb (#p = 0.04 student’s t-test).
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indicating that this region of the channel may be
involved in subcellular trafficking [6]. However, the N-
terminus in our brain isoform has the same exon1b/2
composition as the channel construct used in previous
work with cardiac A39V-Cav1.2 [1], and hence N-term-
inal variations cannot account for the observed differ-
ences between our findings and those reported
previously. Several sequence differences between brain
and cardiac isoforms do exist, however, one of which is
a sequence insertion in the II-III intracellular linker of
the brain isoform that has been hypothesized to aug-
ment protein binding in this region of the channel [21]
(see Additional file 1: Figure S1). Moreover, the study
by Antzelevitch and colleagues [1] utilized YFP tagged
Cav1.2 channels containing exon 8a, whereas the Cav1.2
channels used in our experiments contained exon 8. It
is possible that such splice isoform specific differences,
or the attachment of a large YFP epitope could contri-
bute to the observed differences in our findings com-
pared to those reported previously. In our hands, A39V-
Cav1.2 was able to traffic to the cell membrane as well
as WT-Cav1.2, and the cardiac Cavb2b subunit signifi-
cantly increased surface expression of A39V-Cav1.2 in
tsA-201 cells.
The Cavb subunit has been shown to increase total
expression of Cav1.2 by binding to the I-II intracellular
linker of the channel and preventing ER associated
degradation (ERAD) [22]. We therefore tested whether
A39V-Cav1.2-HA total protein was increased upon
coexpression of Cavb2b and whether A39V-Cav1.2-HA
expressed like WT-Cav1.2-HA without a Cavb subunit
(Figure 1C). Immunoprecipitation of the channels com-
bined with semi-quantification against alpha-actin yield
demonstrated that, in the absence of a Cavb subunit,
the integrated density of A39V-Cav1.2-HA (2.56 +/-
0.48 IDUs) was significantly less than WT-Cav1.2-HA
(4.33 +/-0.66 IDUs, p = 0.04 by students t-test) (Figure
1D). Therefore, A39V-Cav1.2 is either produced to a
lesser extent, or degraded more effectively than WT-
Cav1.2. Since both Cav1.2 constructs were transfected
identically and driven by the same constitutive promo-
ter, the latter of these two possibilities appears more
likely. Our data also reveal that coexpression of either
Cavb2b (5.20 +/-0.25 IDUs) (Figure 1C) or Cavb1b (5.69
+/-0.62 IDUs) (Additional file 2: Figure S2B), results in
a significant increase in A39V-Cav1.2-HA protein levels
(p = < 0.05 by ANOVA) (Figure 1D). This confirms that
the protective role of the Cavb subunit is maintained in
the A39V-Cav1.2 channel. Interestingly, total WT-
Cav1.2-HA protein levels were increased upon coexpres-
sion of Cavb1b (5.05 +/- 0.79 IDUs), but to a lesser
degree than described by our lab previously for a
Cav1.2. We attribute this to a different amino acid
sequence in the N-terminus of the channel [22], perhaps
suggesting that the N-terminus is involved in regulating
Cav1.2 channel stability.
We next evaluated whether the A39V mutation could
alter the functional properties of the neuronal Cav1.2
isoform. In the absence of the Cavb subunit WT-Cav1.2
exhibits a peak current density of -4.4 +/- 0.5, pA/pF at
a test potential of 0 mV. As expected, co-expression of
either Cavb2b (-9.1 +/- 1.4 pA/pF, p = < 0.05 ANOVA),
or Cavb1b (-10.6 +/- 1.1 pA/pF, p = < 0.05 ANOVA)
significantly increases the peak current density of WT-
Cav1.2. The current-voltage relationship of A39V-
Cav1.2 is not statistically different from WT-Cav1.2 in
t h ep r e s e n c eo fe i t h e rC a v b2b (Figure 2A), or Cavb1b
(see Additional file 2: Figure S2C). The A39V-Cav1.2
construct shows a peak current density of -3.3 +/- 0.5,
pA/pF which does not differ from that of the WT chan-
nel and which is increased upon coexpression of
Cavb2b (-9.5 +/-1.6 pA/pF, p =<0 . 0 5A N O V A ) ,o r
Cavb1b (-8.3 +/- 1.0 pA/pF, p = < 0.05 ANOVA). Alto-
gether, these data fit with our biochemical analysis in
Figure 1. All other voltage-dependent properties of
channel activation are similar in A39V-Cav1.2 and WT-
Cav1.2 channels, with or without b subunit co-expres-
sion (Table 1). Moreover, the time course of inactivation
(see Figure 2C) was not statistically different between
A39V-Cav1.2 and WT-Cav1.2, with or without Cavb
subunit co-expression at all potentials tested between
-10 mV and +30 mV (data not shown).
It has been demonstrated that mutations in the car-
diac Cavb2b subunit can affect inactivation of Cav1.2 in
order to produce a Brugada phenotype [23]. Further-
more, the N-terminus of Cav1.2 has been shown to
affect inactivation of the channel in a manner dependent
on the Cavb subunit [15]. We therefore tested whether
the steady-state inactivation properties of A39V-Cav1.2
were different from those of WT-Cav1.2 in the presence
of a Cavb subunit. In the presence of either Cavb2b
(Figure 2B), or Cavb1b (Additional file 2: Figure S2D)
the steady-state inactivation properties of A39V-Cav1.2
are not significantly different from WT-Cav1.2. How-
ever, in the absence of the Cavb subunit, A39V-Cav1.2
displays a significant increase in the slope of the inacti-
vation curve (11.8 +/- 1.4 mV) which is significant when
compared to WT-Cav1.2 (6.9 +/- 0.6 mV, p = < 0.01
students t-test). Furthermore, the A39V-Cav1.2 channel
underwent a greater extent of total inactivation com-
pared to the WT channel as denoted by red asterisks in
Figure 2B (test potentials of -20,-10, +10, and +30 mV,
p = < 0.05 by students t-test). This behavior of A39V-
Cav1.2 could in principle be interpreted as a loss-of-
function; however, as this occurs only in the absence of
Cavb, this effect will not likely manifest itself in native
cells.
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presence of b2b or b1b.( A). The current-voltage relationships of WT and A39V-Cav1.2 with and without b2b. There is no significant difference
in current density, or voltage-dependent properties when comparing WT-Cav1.2 (grey) and A39V-Cav1.2 (light green); or WT-Cav1.2 (black) and
A39V-Cav1.2 (dark green) with Cavb2b. Cavb2b does significantly increase the current density of both WT and A39V-Cav1.2 (p = < 0.05 by one-
way ANOVA). b1b also significantly increased current density of A39V-Cav1.2 (p = < 0.05 by one-way ANOVA) (Additional file 2: Figure S2). (B).
Steady-state inactivation plots of WT and A39V-Cav1.2 with and without b2b. There is no significant difference in the steady-state of inactivation
between WT-Cav1.2 and A39V-Cav1.2 in the presence of b2b or b1b (Additional file 2: Figure S2). The slope of steady state inactivation is
increased for A39V-Cav1.2 when compared to WT-Cav1.2 in the absence of the Cavb subunit (see Table 1) which significantly reduces the
percentage of channels available at marked voltages (*) when compared to WT (p = < 0.05 by students t-test). (C) Voltage clamp protocol for
inactivation curves, and sample traces of WT-Cav1.2 and A39V-Cav1.2 with Cavb2b. Normalized traces of WT-Cav1.2 (black) and A39V-Cav1.2 (dark
green) with Cavb2b illustrating no significant difference in the time course of inactivation. Currents were evoked from a holding potential of
-100 mV to various 4.5 s long conditioning potentials (ranging from -60 mV through +60 mV in 10 mV increments), followed by a test pulse to
+10 mV for 0.5 sec.
Table 1 Current densities and voltage-dependent properties of A39V-Cav1.2 without Cavb, with Cavb2b, or with
Cavb1b
Current Density
(pA/pF)
V1/2 Activation
(mV)
Slope of
Activation (mV)
V1/2 Steady State
Inactivation (mV)
Slope of Steady State
Inactivation (mV)
Cav1.2 + Cava2δ -4.4 +/- 0.5 -9.1 +/- 1.3 4.7 +/- 0.7 -5.4 +/-1.8 6.9 +/- 0.6#
A39V-Cav.2 + Cava2δ -3.3 +/- 0.5 -11.7 +/- 1.5 4.6 +/- 0.9 -7.3 +/- 1.9 11.8 +/- 1.4#
Cav1.2 + a2δ + Cavb2b -9.1 +/- 1.4 * -3.8 +/- 0.8 10.2 +/- 1.4 -7.1 +/- 1.7 11.1 +/- 1.8
A39V-Cav1.2 + Cava2δ +
Cavb2b
-9.5 +/- 1.3 ** -3.0 +/- 1.4 13.0 +/- 2.0 -5.2 +/- 2.8 11.5 +/- 1.2
Cav1.2 + Cava2δ +
Cavb1b
-10.6 +/- 1.1 * -9.0 +/- 0.8 8.8 +/- 1.2 -6.3 +/- 1.1 8.4 +/- 1.2
A39V-Cav1.2 + Cava2δ +
Cavb1b
-8.3 +/- 1.0 ** -6.4 +/- 1.1 8.1 +/- 0.9 -6.8 +/- 1.6 9.3 +/- 0.8
- * indicates significant increase in current density when compared to Cav1.2 without a Cavb subunit; p = < 0.05, ANOVA
- ** indicates significant increase in current density when compared to A39V-Cav1.2 without a Cavb subunit; p = < 0.05, ANOVA
- Data expressed as mean +/- SEM. Current density was determined from a minimum of 24 cells per condition, from three separate transfections. All other values
determined from aforementioned cells which fit the modified Boltzmann, or Boltzmann equations (> 11 cells/per condition)
- # indicates significant difference in slope of steady state inactivation; p = > 0.01, Students T-test
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gada mutation A39V with regard to surface trafficking,
total expression and function within the neuronal
Cav1.2 isoform. Contrary to previous work on the car-
d i a ci s o f o r mo fC a v 1 . 2s h o w i n gal o s so fc e l ls u r f a c e
trafficking of A39V-Cav1.2 in the presence of Cavb2b,
we find that both cardiac Cavb2b and neuronal Cavb1b
equally regulate the neuronal forms of mutant and WT
Cav1.2 channels, and that the mutation does not alter
the behavior of the neuronal channel in the absence of
the Cavb subunit. The concept of channel isoform-
dependent effects of disease causing mutations is not
without precedent [13,14] and in the case of the Bru-
gada mutation A39V may perhaps explain why patients
afflicted with this mutation do not exhibit a neuronal
phenotype.
Additional material
Additional file 1: Figure S1. (A). Sequence alignment of the N-terminus
of the two human A39V-Cav1.2 variants used in previous work [1]
(accessions Z34815 & AJ224873) and the rat short N-terminus used in
this study (M67515). Polymorphisms between rat and human channels
are denoted by an ‘X’ below the amino acid position. Note however that
the polymorphism (in red) present in the rat clone was mutated back to
aspartic acid to match the human channels as addressed in the
Methods. Both studies used short N-terminal splice variants of Cav1.2,
which incorporate exon 1b. (B). Sequence alignment of the exon 8/8a
segment of Cav1.2 used in each study. Note that YFP-containing exon 8a
Cav1.2 was used for trafficking experiments in previous work [1], while
exon 8 containing Cav1.2 was used in our study. Exon 8 (in red) is
identical between human and rat. Polymorphisms detected between
exon 8/8a are denoted by an ‘X’ below the amino acid position. (C).
Sequence alignment of a portion of the II-III intracellular linker of the two
human variants used in previous work [1] and the rat Cav1.2 channel
used in our work. Note the inclusion of an inserted sequence in the rat
channel which has been previously reported [21]. (D). Sequence
alignment of the most divergent portion of the C-terminus of the two
human cardiac sequences used in previous work [1] and the rat brain
isoform used in our study.
Additional file 2: Figure S2. (A). Cavb1b increases the fluorescence per
cell of WT-Cav1.2-HA (p = < 0.05 by one-way ANOVA), but not A39V-
Cav1.2-HA (p = > 0.05 by one-way ANOVA). (B). b1b significantly
increases the total protein expression of A39V-Cav1.2-HA (p = < 0.05 by
ANOVA), but not WT-Cav1.2-HA. (C). Cavb1b significantly increases
current density of WT and A39V-Cav1.2 (p = < 0.05 one-way ANOVA). (D).
Steady-state inactivation properties of A39V-Cav1.2 are the same as WT
in the presence of b1b, for details see Table 1.
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